Patient Stories
See how clonoSEQ helped patients like you have confidence in their treatment plans
A DLBCL patient discusses how MRD testing provides an early warning system for his disease and how he and his doctor acted as a co-pilots in his care
Jim’s Story
Jim’s Story
A DLBCL care partner sharing her experience and a message of hope.
Anne’s Story
A CLL patient discusses his experience with MRD testing
Lee’s Story
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.